NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

CEO

Dietrich Stephan

Employees

Country

United States

ISIN

US64132K1025

WKN

000A2PNYF

Listings

0 Comments

Share your thoughts

FAQ

What is NeuBase Therapeutics stock price today?▼

The current price of NBSE is $0.38 USD — it has decreased by -3.2% in the past 24 hours. Watch NeuBase Therapeutics stock price performance more closely on the chart.

What is NeuBase Therapeutics stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange NeuBase Therapeutics stocks are traded under the ticker NBSE.

What is NeuBase Therapeutics revenue for the last year?▼

NeuBase Therapeutics revenue for the last year amounts to 0 USD.

What is NeuBase Therapeutics net income for the last year?▼

NBSE net income for the last year is -33.78M USD.

How many employees does NeuBase Therapeutics have?▼

As of August 19, 2026, the company has 37 employees.

In which sector is NeuBase Therapeutics located?▼

NeuBase Therapeutics operates in the Technology sector.

When did NeuBase Therapeutics complete a stock split?▼

The last stock split for NeuBase Therapeutics was on June 15, 2023 with a ratio of 1:20.

Where is NeuBase Therapeutics headquartered?▼

NeuBase Therapeutics is headquartered in Pittsburgh, United States.